Introduction of the TKIs has vastly improved the prognosis for CML patients. For patients diagnosed in chronic phase of CML, life expectancy is similar to that of the general population.
Despite the introduction of the TKIs, up to 5% of patients will still progress to the accelerated and blast phases. For these patients, the prognosis is inferior to that of patients remaining in the chronic phase.
For the 5-10% of patients diagnosed in the accelerated or blast phases, response to TKIs is poor which affects their prognosis.
